Status:
COMPLETED
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lead Sponsor:
John Byrd
Conditions:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a phase I/II study of the combination of etanercept and rituximab in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This combination is proposed to impr...
Detailed Description
Rationale: Previous research has demonstrated that rituximab has efficacy against chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Rituximab is a monoclonal antibody used to tr...
Eligibility Criteria
Inclusion
- Must have been previously treated CLL/SLL
- Must have CD20 expression
- ECOG PS =\<3
- No prior Campath-1H
- No active infection requiring antibiotics
- No concurrent immunosuppressive therapy
- No prior history demyelinating neurologic disease
- No active viral hepatitis
Exclusion
- No pregnant or breastfeeding women
- ECOG PS =4
- Life expectancy of \>12 weeks
- Patients with bilirubin or creatinine\>3.0 mg/dl
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00201682
Start Date
October 1 2002
End Date
August 1 2009
Last Update
February 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University Medical Center
Columbus, Ohio, United States, 43210